This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): Gastrom
Description: Ecabet sodium is derived from pine resin. It represents a new class of molecules that increase the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. Mucin is a glycoprotein component of tear film that lubricates while retarding moisture loss from tear evaporation.
In laboratory tests on gastric juices taken from patients, Ecabet sodium reduced pepsin activity — a known cause of ulcers — by up to 78% cent and caused the mucus lining the stomach to thicken, providing extra protection from the gastric juices.
Deal Structure: Ecabet sodium is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis. In November 2004, Ista acquired U.S. marketing rights to ecabet sodium for the treatment of dry eye syndrome under a license agreement with Senju.
Bausch + Lomb and ISTA
In March 2012, Bausch + Lomb and ISTA Pharmaceuticals announced that they have signed a definitive agreement under which Bausch + Lomb will acquire ISTA. This acquisition closed in June 2012.
Bausch + Lomb and Valeant
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.
In August 2013, Valeant announced it has completed the acquisition of Bausch + Lomb.
Partners: Senju Pharmaceutical Co., Ltd.
Ecabet sodium News
Additional information available to subscribers only: